Thomas Prebet was named leader of myeloid malignancies on the Disease Aligned Research Team, and Amer Zeidan was named director of the Hematology Early Therapeutics Program at Yale Cancer Center.
In these new roles, Prebet and Zeidan will work closely with Stephanie Halene, interim chief of hematology at YCC.
Prebet is an associate professor of medicine (hematology) and is focused on developing clinical trials for myeloid malignancies and translational advances for patients with acute myeloid leukemia and myelodysplastic syndromes. In his new role as DART leader for myeloid malignancies, he will oversee the clinical trial team for myeloid malignancies and work to develop a complete portfolio of trials for our patients.
Zeidan is an associate professor of medicine (hematology) and is the Yale principal investigator for multiple NCI-sponsored and clinical trials in myeloid malignancies. Zeidan is also chairing the steering committee for a large pharma-sponsored randomized trial of myelodysplastic syndromes. As director of the Hematology Early Therapeutics Program, Zeidan will partner closely with Patricia LoRusso, associate cancer center director for Experimental Therapeutics at YCC, to develop a comprehensive phase I clinical trial portfolio for patients with hematologic malignancies.
A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.